---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-018997"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T20:46:11.830648+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition Corp. II to merge with BridgeBio Oncology Therapeutics in $461M deal

## Summary
- Equity value of $461M; BBOT stockholders to receive shares of PubCo common stock.
- PIPE investments of ~$260M committed, including $75M from Cormorant; minimum $400M cash required at close.
- Closing expected after SEC effectiveness, shareholder approvals, and Nasdaq listing; drop-dead date Oct 31, 2025.
- Sponsor to forfeit shares if Helix Closing Cash < $400M; non-redemption agreements cover 450,900 Class A shares.
- Lock-up on Sponsor and existing Helix investors' shares for one year post-Closing.

## SEC filing metadata
- accession: 0001213900-25-018997
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000121390025018997/0001213900-25-018997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000121390025018997/ea0232544-8k425_helix2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-018997
- JSON: https://secwatch.observer/filing/0001213900-25-018997.json
- Plain text: https://secwatch.observer/filing/0001213900-25-018997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.